




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/574, C07K 16/18		A1	(11) International Publication Number: WO 98/43091 (43) International Publication Date: 1 October 1998 (01.10.98)
<p>(21) International Application Number: PCT/GB98/00881</p> <p>(22) International Filing Date: 23 March 1998 (23.03.98)</p> <p>(30) Priority Data: 9705949.7 21 March 1997 (21.03.97) GB</p> <p>(71) Applicant (for all designated States except US): PROTEOME SCIENCES PLC [GB/GB]; Coveham House, Dowsndide Bridge Road, Cobham, Surrey KT11 3EP (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): HOCHSTRASSER, Denis, Francois [CH/CH]; Chemin de la Savonniere 27, CH-1245 Collonge-Bellerive (CH). REYMOND, Marc, Andre [CH/CH]; Chemin des Coprins 3, CH-1222 Vesenaz (CH). PEINADO, Miguel Angel [ES/ES]; Institut de Recerca Oncologica, Autovia Castelldefels, 2.7, E-08907 L'Hospitalet (ES).</p> <p>(74) Agent: LUCAS, Brian, Ronald; Lucas & Co., 135 Westhall Road, Warlingham, Surrey CR6 9HJ (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: DIAGNOSIS OF EPITHELIAL CELL ABNORMALITIES</p> <p>(57) Abstract</p> <p>A method of diagnosis of solid epithelial tumours or other abnormalities such as rectal colitis, which comprises size-separating stroma from epithelial cells, separating the epithelial cells from most of the other tissue still present, by reacting the tissue with a monoclonal antibody specific for epithelial cells, collecting the reacted cells bound to the antibody and releasing them from the antibody, whereby the sample contains at least 90 percent epithelial cells by volume of the total tissue of the sample and comparing at least one phenotypic or genotypic characteristic of the sample with corresponding normal epithelial cells.</p>			

Colorectal Epithelia Cell 2-D PAGE Reference Map



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon			PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

DIAGNOSIS OF EPITHELIAL CELL ABNORMALITIESBackground of the invention1. Field of the invention

This invention relates to the diagnosis of tumours
5 and other abnormalities of body cells.

2. Description of the related art

There is a need for improved methods of diagnosis
of tumours, particularly to determine whether there is
any residual disease after surgery or therapy has taken
10 place. This is particularly necessary to detect me-
tastases. The present invention relates specifically to
epithelial tumours and other abnormalities of epithelial
cells. The term "diagnosis" as used herein includes the
15 obtaining of any kind of information relating to the
existence of or condition of a tumour or other abnormal-
ity, and includes prognosis.

In clinical practice, the TNM (tumour node metasta-
sis) staging system, "TNM classification of malignant
tumours", UICC, Springer, Berlin (1992), still offers
20 the best prognostic information in the case of epithe-
elial tumours, because it describes the extent of tumour
involvement at the time of diagnosis. Nevertheless,
this system has serious limitations, since some patients
25 with early tumour stages develop metastases after cura-
tive surgery, even if the tumour does not reappear
locally. Other patients with advanced stages of cancer
remain disease-free after the surgery. New diagnostic
markers for these tumours are clearly needed.

Particularly in colorectal cancer (cancer of the
30 colon or rectum), there are very few diagnostic markers.
In principle, further markers might become available if
the genotype or phenotype of the tumour cells could be
compared with normal cells. However, the interpreta-
tion of comparative studies on colorectal cancer has so
35 far proved disappointing, because of inter-sample varia-

tions and methodological problems. For example, comparison of protein fingerprints obtained from tumour cell lines with those obtained from human colonic crypts proved to have no clinical implications, see Ji et al., 5 *Electrophoresis* 15, 391-405 (1994). Another problem is the physiologically high content of proteases in the intestinal mucosa.

Summary of the invention

It has now been found that a proper comparison can 10 be made between the genotype or phenotype of samples from normal and tumorous or other abnormal tissue, using a procedure which enables epithelial cells to be isolated as cellular material substantially free of stroma (connective tissue) and other impurities. This cell 15 preparation is sufficiently pure to enable differences between the normal and abnormal cells to be identified and used to make protein or nucleic acid maps. These maps have enabled further markers for colorectal cancer to be found. Further, the procedure has a general 20 applicability which extends to other kinds of solid epithelial tumours and other abnormalities found in epithelial cells from a variety of types of body tissue.

The invention thus provides a method of diagnosis 25 of an abnormality in epithelial cells, especially tumours, in a sample of tissue taken from the location of the suspected abnormality, especially tumorous, epithelial cell-containing tissue of a patient, especially a human patient. The method comprises (consists of or includes) size-separating stroma from epithelial cells, 30 separating the epithelial cells from most of the other tissues still present, by reacting the tissue with a monoclonal antibody specific for epithelial cells, collecting the reacted cells bound to the antibody and releasing them from the antibody, whereby the sample 35 contains at least 90 percent epithelial cells by volume

of the total tissue of the sample and comparing at least one phenotypic or genotypic characteristic of the sample with corresponding normal epithelial cells. Preferably the basis for determining that the purified sample 5 contains at least 90 percent epithelial cells by volume of total tissue of the sample is by fluorescence-activated cell sorting using anti-cytokeratin antibodies after membrane permeabilization of the cells.

By use of the above method, two dimensional gel 10 electrophoretic maps have been produced from the epithelial cells of normal and colorectal tumour-bearing patients and compared. This has resulted in the finding that certain protein spots are over-produced or under-produced in colorectal tumour cells.

15 Brief description of the drawings

Fig. 1 is a 2D-gel map of proteins present in normal colorectal epithelial cells of a cell preparation produced by the method of the invention.

Description of the preferred embodiments

20 While the invention relates principally to colorectal tumours, it is applicable to any other solid tumour containing epithelial cells, in particular to lung, breast, stomach, pancreas, prostate and kidney tumours, for example. Further, it is applicable to detecting 25 other abnormalities of epithelial cells, such as are associated with rectal colitis, Crohn's disease or diverticulitis, for instance.

The most preferred procedure of the invention for separating the epithelial cells sufficiently to form the 30 highly pure cell preparation comprises reacting the tissue with a monoclonal antibody specific for epithelial cells and collecting the reacted cells. The monoclonal antibody can be any which reacts with an appropriate epithelial cell surface protein, especially a 35 receptor. A particularly preferred such antibody is

Ber-EP4, as described by U. Latza, J. Clin. Pathol. 43, 213 (1990). This antibody is available in the form of magnetic beads ("Dynabeads") coated with it. Since the magnetic beads can be readily separated magnetically, in 5 the usual way in assay technology, the epithelial cells can be collected magnetically and then washed from the beads.

Another way of separating the cells would be by a non-magnetic heterogeneous method using the same or 10 another ligand such as a monospecific antibody or a peptide which binds strongly to an epithelial cell receptor. The ligand is bound to a solid phase, which is subsequently washed to remove the epithelial cells which have become bound thereto.

15 Conveniently, the preparation of epithelial cells is used to determine a phenotypic difference between normal and abnormal cells. This may be in terms of the presence of a greater or smaller concentration in the abnormal cells than in the normal cells. This possibility includes the complete absence of a protein from one 20 or the other.

The invention is useful in its own right for tissue mapping, to show differences between normal and abnormal tissue, whether these differences have a genetic origin 25 or not and whether or not they have any value in relation to prognosis of the disease. Two particularly preferred methods of mapping are protein and nucleic acid mapping. Proteins can conveniently be mapped by two dimensional gel electrophoresis. The spots are 30 defined by reference to a 2D-PAGE carried out on a protein extract of the sample by a method comprising (1) centrifuging 1000 microlitres of the protein extract at 10,000 x G at room temperature for 5 minutes 35 to form a pellet, dissolving the pellet in 300 microlitres of a solution containing 8M urea, 40% CHAPS, 40

mM Tris, 65 mM dithioerythritol and a trace of bromophenol blue and loading the resulting sample solution onto 3 mm wide x 180 mm long strips of immobilised pH gradient (IPG) polyacrylamide gel having a non-linear, 5 sigmoidal (S-shaped) pH gradient;

(2) rehydrating the gel overnight with 25ml of an aqueous solution of 8M urea, 2% w/v CHAPS, 10 mM dithioerythritol and 2% v/v buffers of pH 3.5 to 10 and a trace of bromophenol blue;

10 (3) loading the sample solution onto the IPG gel strips for first dimension electrophoresis and running the electrophoresis at a voltage which is increased linearly from 300 to 3500 V during 3 hours, then for 3 additional hours at 3500 V, and finally for 17 hours at 5000 V;

15 (4) treating the IPG gel strips with 100ml of an aqueous solution containing 50 mM Tris-HCl, pH 6.8, 6M urea, 30% w/v glycerol, 2% w/v SDS, 2.5% v/v iodoacetamide and a trace of bromophenol blue for 5 minutes, to resolubilize the proteins and reduce any -S-S- bonds;

20 (5) preparing a polyacrylamide gradient slab gel 160 x 200 x 1.5mm from an aqueous solution containing 9 to 16% acrylamide monomer, 2.6% diacryloylpiperazine cross-linking agent, 5 mM sodium thiosulfate, 0.05% tetramethylethylenediamine, 0.1% ammonium persulfate and 0.375M Tris-HCl buffer, pH 8.8, all percentages being w/v, 25 overlaying with sec-butanol for two hours, replacing the sec-butanol with water and standing for 15 hours, overlaying the slab gel with an aqueous solution containing 0.5% agarose, Tris-glycine-SDS at pH 8.3, at 30 25 mM Tris, 198 mM glycine and 0.1% SDS, heated to 70°C and loading the IPG gel strips thereon for second dimension electrophoresis;

(6) running the second dimension electrophoresis at a constant 40 mA/gel and at 10°C for 5 hours; and

35 (7) silver staining the gels and scanning them with a

laser densitometer, to give a computer-generated image of the stained gel.

RNA can be mapped by amplifying the cellular RNA (preferably total cellular or total cytoplasmic; mRNA is 5 much more difficult to extract from some samples) and running the resultant amplified nucleic acid (conveniently as DNA) on a gel to provide a characteristic band pattern (so-called fingerprint). Most preferably the 10 two maps are correlated, in a search for a protein which is over-produced or under-produced in tumour cells and is accompanied by an increase or decrease in RNA production.

Preferably, the invention is used to detect and 15 test potential new markers for cancers of various kinds, according to the tissue of origin. Once a marker has been thus detected, it may well be possible to eliminate some of the steps of sample preparation and simply compare the tumorous and normal tissue for the marker. 20 However, whether this is possible will depend on the individual markers.

The markers may be detectable as proteins by any of 25 the conventional means, including two dimensional gel-electrophoresis, western blotting with an antibody against the protein, a combination of western blotting with one dimensional gel-electrophoresis, immunoassay (especially enzyme-linked, enhanced chemiluminescent assay).

A method of assay for presence or amount of the 30 marker in a sample from a patient preferably comprises (consists of or includes) a gel electrophoretic method or immunological method or some combination of the two. Conveniently, the method of testing is wholly or predominantly immunological, i.e. typically it involves interaction between the protein of the invention and an 35 antibody thereto or between an antibody of the invention

and another antibody. Immunological methods preferably comprise Enzyme-Linked Immuno-Sorbent Assay (ELISA) or western blotting (also referred to as immunoblotting).

For immunological assay, antibody is required. To obtain antibody, it is first necessary to purify and identify at least one protein of the marker spots or a protein sufficiently immunologically similar thereto as to have the same specific epitope. The protein may be purified by standard methods. Thus, the spot is excised from the 2D-gel (or electroeluted into solution or electro-transferred to a membrane and excised from the membrane) and, de-stained by a known method.

The purified protein can then be sequenced by any of the well-known methods, including N-terminal sequencing by Edman degradation (or, if the N-terminus of the protein is blocked, applied to a fragment cleaved by CNBr or by digestion with a peptidase). Mass spectrometry may also be used for sequence determination, especially the method of M. Wilm et al., *Nature* 379, 466-469 (1996), the disclosure of which is herein incorporated by reference. After the protein has been sequenced, it can be checked in sequence databases for similarity to other known proteins. If the protein is already known or very similar to one which is already known, an antibody will probably be commercially available. Otherwise, an antibody will have to be raised for the purposes of an immunological method of assay of the marker protein.

The purified protein can be used directly to raise antibodies or a synthetic protein or peptide thereof could be made by recombinant DNA means, using a pool of labelled degenerate oligos as a probe or primer.

With knowledge of the full amino acid sequence of the protein, various peptides thereof or even the full length of protein can be synthesised by the usual me-

thods of peptide synthesis. Peptides thereof can be tested for reaction with the said polyclonal antibodies raised against the full length protein. These peptides which give a reaction can then be synthesised and used 5 in place of the full length protein to raise antibodies or in competition or displacement assays for the protein present in the sample.

The term "antibody", as used herein, includes polyclonal, monoclonal antibodies, fragments of antibodies such as Fab and genetically engineered antibodies. 10 The antibodies may be chimeric or of a single species.

Although the antibodies raised initially may be polyclonal, monoclonal antibodies can be prepared using the well known Köhler-Milstein method. Conveniently, 15 the ascites fluid from mouse-mouse hybridomas is used and screened against the proteins purified from spots cut from a preparative gel.

Antibodies may also be raised by expressing the immunoglobulin gene on the surface of a bacteriophage 20 and screening the resultant clones against the specific antigen, i.e. the marker protein of the present invention. See, e.g., S.L. Morrison in "Molecular Biology and Biotechnology" ed. Robert A Meyers, VCH Publishers Inc. 1995, at page 37, the disclosure of which is herein 25 incorporated by reference.

Protocols for western blotting are well known. After transfer of the protein from the electrophoretic gel, which may be a 1D-gel or a 2D-gel, to a suitable membrane, preferably of nitrocellulose or polvinylidene 30 difluoride, the membrane is blocked to prevent non-specific adsorption of immunological reagents. Typical blocking solutions are of skimmed milk powder or bovine serum albumin. After blocking, the protein can be detected directly or indirectly. Direct detection uses 35 labelled primary antibodies, while in indirect detection

a second antibody is raised against the first and the second antibody is labelled. The antibodies are usually labelled with an enzyme such as peroxidase or alkaline phosphatase or with a ligand which has a high affinity 5 for a co-ligand, such as biotin, which has a high affinity for streptavidin and avidin. The protein is then detected by adding an enzyme substrate, conveniently a color-forming one, to read out the enzyme label or an enzyme-labelled co-ligand plus a substrate for the 10 enzyme if a high affinity ligand type of label was used.

An alternative method of quantifying or detecting the presence of the protein is the use of immunoassays, preferably ELISAs, which may be performed on the epithelial cell sample or on protein, isolated or partly 15 isolated by 1D or 2D-gel electrophoresis, transferred to a membrane by blotting. Types of immunoassay useful in this invention include antibody capture assays, antigen capture assays (also called competition or displacement assays) and the two antibody sandwich immunoassay. All 20 the immunoassays require labelled marker protein, antibodies or secondary reagents for detection or quantitation. The labels described above for western blotting may be used. The labels may be "read out" or detected by any conventional method, e.g. in an ELISA by using 25 color-forming, fluorescent or chemiluminescent means. Enhanced chemiluminescent assays are particularly preferred and several commercial kits for such assays are known in connection with peroxidase and alkaline phosphatase enzyme labels.

30 Test kits appropriate to the above and other forms of assay will be apparent to those skilled in the art. Preferred such kits are those for an antibody capture assay and comprise a first an antibody to a protein marker and a labelled second antibody thereto, provided 35 either separately or in the form of a linked double

antibody. The test kits may optionally include any of a variety of supports or solid phases, especially plastic tubes and microtiter plates. Procedures for assisting the binding of antigens or antibodies to such supports 5 are well known.

Although heterogeneous assays are cheap and well understood in the art, homogeneous assays may also be used in this invention.

Immuno-PCR may be used as a method of amplifying 10 the signal of an immunoassay described above. In this technique the antibody is covalently linked to a piece of arbitrary DNA comprising PCR primers, whereby the DNA with antibody attached is amplified by the PCR. See Hendrickson et al., Nucl. Acids Res. 23, 522-529 (1995), 15 the disclosure of which is herein incorporated by reference.

It is, of course possible, to assay the marker protein by a method which comprises at least one dimension of gel electrophoresis. The gel electrophoresis 20 protocols are not to be regarded as limited to those described herein. They may be varied considerably. The sample is first disrupted, e.g. with a high molar concentration of urea, detergents and dithiothreitol or dithioerythritol to break -S-S- bonds. The first dimension gel is then run in an ampholyte mixture which 25 establishes a pH gradient across the gel, so that the proteins migrate to their isoelectric point, i.e. to a point at which the pH of the gel within the pH gradient established by the ampholytes is equal to the charge on 30 the protein. At this stage, there may be sufficient resolution of the marker spots from others to provide an adequate test for the tissue abnormality. If not, a western blot or immunoassay, using antibody to the 35 protein of the invention, may be performed. Alternatively, the second dimension electrophoresis may then be

performed. Here the first dimension gel is loaded, transversely to the direction of current, onto a second gel. This is normally an SDS-PAGE gel, the principle being that charges on the protein are swamped by the 5 effect of the SDS, so that the gel separates the proteins according to molecular weight. This is aided by a higher acrylamide concentration.

Abnormal genotypes may be detectable as RNA by any of the conventional means for detecting cellular RNA, especially probing with labelled DNA specific for the RNA, preferably at two sites in the DNA encoding the protein so as to increase the stringency of binding of the probe to the sample. Labelled oligonucleotides of length, say 17 to 40 nucleotides are usual for this 10 purpose. Preferably the RNA extracted from the sample would be amplified, e.g. by polymerase chain reaction, before carrying out this assay. Since the sample RNA will usually have to be amplified anyway, it may be more convenient to use a labelled amplification procedure, 15 such as PCR using a labelled primer. In this connection, it has been found that a random arbitrary primer can be very useful where the genotype of the disease state is unknown.

The following Examples illustrate the invention.

25 Example 1

Materials and Methods

Isolation of human colonic crypts

Immediately after human bowel resection surgery for various medical reasons, the surgical specimen was 30 stored on ice. After washing with iced phosphate buffered saline (PBS) solution, a fragment of mucosa (5 x 5cm) was dissected from a healthy portion of tissue, as far removed as possible from the site of disease. The mucosa was then immersed in an ice-cold PBS solution 35 containing EDTA 3mM and a freshly prepared cocktail of

proteases inhibitors (leupeptine 50 micrograms/ml, PMSF 0.2 mM and benzamidine 0.8 mM). Crypts were scraped away from the basal membrane with a scalpel, and then gently pressed through a steel mesh having a pore size 5 of 300 micrometres to separate epithelial cells from stroma. The cell suspension obtained in this way was then filtered through a nylon mesh having a pore size of 200 micrometres. This permitted the isolation of single, or small clusters of epithelial and other cells 10 (lymphocytes, macrophages, etc). The stroma (connective tissue) was not altered by this mechanical procedure and could theoretically be used for further analysis.

Isolation of epithelial cells

After washing and centrifuging the cells at 350 x g 15 for 10 min at 4°C, they were resuspended in the above mentioned solution at a concentration of 2×10^7 cells/ml. This suspension was then incubated at 4°C for 30 minutes with anti-Epithelial Cell "Dynabeads" coated with Ber-EP4 antibodies in accordance with the instructions of the manufacturer (Deutsche Dynal GmbH, Hamburg, 20 Germany). The cells were then collected with a magnetic particle concentrator (MPC-1, Deutsche Dynal GmbH, Hamburg, Germany) and washed five times. A cell count and viability check were performed using trypan blue and 25 showed over 90% viable cells. This first part of the procedure required no more than 90 minutes.

Control

The nature of the cell samples was assessed after 30 labelling the preparation products with fluorescein-conjugated anti-cytokeratin antibodies (CAM 5.2, Perkin-Elmer, Norwalk, Connecticut, USA) for 45 min, in accordance with the instructions of the manufacturer. The samples were then sorted qualitatively with a Fluorescence-Activated Cell Sorter (Epics, Coulter-Immunotech, 35 Hamburg, Germany). It was thus estimated that the

sample contained at least 90% epithelial cells by volume of total tissue of the sample at that stage.

Denaturation

5 After centrifugation, the pellets were denatured with urea 8M, CHAPS (4% w/v), Tris (40mM) and DTE (65 mM) in accordance with SWISS-2DPAGE protocols, Sanchez et al., Electrophoresis 16, 1131-1151 (1995), and stored at -20°C.

Analytical 2-D PAGE

10 Total protein in each sample was assayed as described by the well known Bradford method. 100 micrograms of normal human colonic epithelial cell protein samples were separated by 2-D PAGE. A commercial sigmoidal immobilized pH gradient (IPG) ranging from pH 3.5 15 to 10.0 (18cm) was used for the first dimension. After equilibration, the IPG gel strips were transferred onto vertical gradient slab gels (9-16% acrylamide) for the second dimension, and run with the Laemmli-SDS-discontinuous system. The crosslinker used was piperazine diacrylyl (PDA 2.6%), and the adjunct catalyst sodium thiosulfate (5mM). A full description of the 20 method is given in the Summary of the Invention above.

Preparative 2-D PAGE

25 Three mg of normal protein samples were separated by 2-D PAGE and electro-transferred onto PVDF membranes. A commercial immobilized pH gradient (IPG) ranging from pH 3.5 to 10.0 was used for first dimensional separation. In-gel sample rehydration was used, which enabled a higher sample loading, increased resolution and shorter 30 running time. After equilibration, the IPG gel strips were transferred onto vertical gradient slab gels (9-16% acrylamide) for the second dimension. Electro-blotting onto PVDF membranes was then effected using a home-made semi-dry apparatus with 10% methanol and 10 mM 35 CAPS as buffer (pH 11) at 200 V for 2 h. The membranes

were stained with amido black.

Identification of proteins

Gel matching

After the laser densitometer scanning, 2-D PAGE 5 image analysis was carried out using the MELANIE II software package (Bio-Rad, CA). Protein spots were detected and quantified automatically. The optical density, area and volume were computed and directly related to protein concentration. The relative optical 10 density and relative volume were also calculated to correct for differences in gel loading and staining. The experimental pI and MW of the spots, as well as protein identification, were deduced by the MELANIE II image analysis software (Bio-Rad, Hercules, California, USA) 15 from the liver SWISS-2DPAGE reference map, Sanchez et al. (1995) referred to above.

Microsequencing

PVDF membranes were stained with Amido Black, 20 destained with water, and dried. The spots of interest were excised, dried under nitrogen, and kept in Eppendorf tubes at -20°C until microsequencing was performed. Ten to fifteen Edman degradation cycles were performed 25 for each spot and the SWISS-PROT database, see Bairoch et al., Nucleic Acids Res. 22, 3578-3580 (1994) was searched to establish the identity of already known proteins.

Immunoblotting

After electrophoretic transfer onto PVDF membranes, 30 the latter were blocked with 10 mM Tris-HCl (pH 7.0), 500 mM NaCl, 0.05% Tween-20 and 0.5% non-fat dry milk prior to incubation with the primary antibodies. Horse-radish peroxidase-conjugated goat anti-rabbit and anti-mouse antibodies were used at a 1/1000 dilution as 35 secondary antibodies. Blots were developed using enhanced chemiluminescence and X-ray film as described by

Boehringer Mannheim. A monoclonal antibody anti-TCTP was used as an internal marker for control and comparison with reference maps.

(5) Results

5 The above-described size-separation and magnetic separation using "Ber-EP4" coated "Dynabeads" permitted enrichment of the samples to over 95% epithelial cells. This pure state was assessed by a second consecutive staining using fluorescein-conjugated anti-cytokeratin 10 antibodies followed by Fluorescence Activated Cell Sorting. A quality control using scanning electron microscopy showed no degradation of the cell surfaces. Contamination by blood, as assessed by serum albumin, was low after washing and enrichment. Comparison of 15 samples before and after separation with the "Dynabeads" showed an improvement in contrast and disappearance of degradation patterns. A mean number of 900-1200 spots/gel was obtained using silver staining.

Spots relating to 40 proteins were sequenced and 20 identified as listed in Table 1. A protein master map of the normal colonic epithelial cells was defined (Figure 1). A key to Figure 1 is provided in the following Table, in which all pI and molecular weight values are apparent (not absolute). Using immunoblotting, expression of proteins having a possible diagnostic or prognostic significance in tissue abnormalities such as colorectal cancer was assessed. In particular, 25 protein families CD44, Mn-SOD, EGF-receptor, PAI-1, hsp70 and PMS2 were localized.

30 Examples of references relating to the implication of the above proteins in the diagnosis or prognosis of tissue cell abnormalities are as follows:

EGFR: R. Seshadri et al., Int. J. Cancer, 69, 23-27 (1996)

35 CD44: L. H. Finke et al., The Lancet, 345, 583 (1995);

- 16 -

J. Mulder, *The Lancet* 344, 1470-1472 (1994); Z. Nihei et al., *Surgery Today*, 26, 760-761 (1996)
PMS2: B. Liu et al., *Nature Medicine*, 2, 169-174 (1996)
MnSOD: A.M.L. Janssen et al., Abstract No. 1327, Proceedings of the 18th Meeting of the American Association for Cancer Research, Washington D.C., April 20-24, 1996, 37, 194-195 (1996);
I. Katsumi et al., JICST Abstract Accession No. 97A0705439 (1997);
10 HSP-70: J. Stulik et al., *Electrophoresis* 18 (3-4), 625-628 (1997).

Similar work can be carried out on chopped pieces of tumour tissue to yield gels which produce spots representing proteins which are over- or under-expressed 15 in the tumour tissue. Comparison of the maps, especially using MELANIE II software, enables proteins of diagnostic or prognostic significance to be identified. Examples are given in a co-pending PCT Patent Application of Electrophoretics International plc et al. filed 20 at the UK Receiving Office on 23rd March 1998, claiming the same priority, and entitled "Diagnosis of Colorectal Cancer and Proteins and Antibodies for Use Therein", the disclosure of which is herein incorporated by reference.

The preparation of the sample to enrich it in 25 epithelial cells has the advantage that reproducible patterns can be obtained even when the stroma (the intercellular connective tissue) differs in different samples. In this way, samples are freed from blood, stool material, lymphocytes etc.

30

- 17 -

Abbreviated Name	Protein Description	Apparent PI	Apparent MW
GRP75	MITOCHONDRIAL STRESS-70 PROTEIN PRECURSOR	5.40	73173
GRP75	MITOCHONDRIAL STRESS-70 PROTEIN PRECURSOR	5.32	73173
ER60	PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR	5.49	52703
ER60	PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR	5.70	52377
ER60	PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR	5.58	52485
PHDB	PYRUVATE DEHYDROGENASE E1 COMPONENT, BETA SUBUNIT PRECURSOR	5.38	34062
C7S5D	CATHEPSIN D PRECURSOR	5.56	27960
C7S5D	CATHEPSIN D PRECURSOR	5.39	27220
KCY	POSSIBLE CYTOLYKATE KINASE	5.42	21346
RPL12	60S RIBOSOMAL PROTEIN L12	5.31	11038
ATPM	ATP SYNTHASE COUPLING FACTOR 6, MITOCHONDRIAL PRECURSOR	5.31	11038
HBB	HEMOGLOBIN BETA CHAIN	6.24	10204
HSPD1	MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR	5.05	56668
HSPD1	MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR	5.16	56084
HSPD1	MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR	5.09	56200
ER31	ENDOPLASMIC RETICULUM PROTEIN ERP 31 PRECURSOR	6.13	26432

- 18 -

Apparated Name	Protein Description	Apparent PI	Apparent MW
ECHM	ENOYL-COA HYDRATASE, MITOCHONDRIAL PRECURSOR	5.95	25594
NDUFR2	NADH-UBIQUINONE DEHYDROGENASE 24 KD SUBUNIT PRECURSOR	5.85	23060
MER 5	MER 5 PROTEIN (FRAGMENT)	6.07	22824
MRPL12	MITOCHONDRIAL 60S RIBOSOMAL PROTRIN L7/L12 PRECURSOR	5.01	17462
HBG	HEMOGLOBIN BETA CHAIN	6.44	11163
B2M	BETA-2-MICROGLOBULIN PRECURSOR	6.40	11038
CALR	CALRETICULIN PRECURSOR	4.41	58700
ATP5B	ATP SYNTHASE BETA CHAIN, MITOCHONDRIAL PRECURSOR	4.93	49118
ACTB	ACTIN, CYTOPLASMIC 1 (BETA-ACTIN)	5.05	41396
ACTB	ACTIN, CYTOPLASMIC 1 (BETA-ACTIN)	5.11	41497
SPTB1	SPECTRIN BETA CHAIN	5.60	24976
MTL1	MYOSIN LIGHT CHAIN	5.06	20750
ATP5D	ATP SYNTHASE DELTA CHAIN, MITOCHONDRIAL PRECURSOR	4.50	13360
COX5A	CYTOCHROME C OXIDASE POLYPEPTIDE VA PRECURSOR	4.80	12166
TXN	THIOREDOXIN (ATL-DERIVED FACTOR)	4.84	11163
SOD1	SUPEROXIDE DISMUTASE (Cu-Zn)	5.42	16331

Abbreviated Name	Protein Description	Apparent PI	Apparent MW
SOD1	SUPEROXIDE DISMUTASE (Cu-Zn)	5.70	16248
GALS1	GALECTIN-1	4.93	12076
COX5B	CYTOCHROME C OXIDASE POLYPEPTIDE VB PRECURSOR	5.62	12121
SOD2	SUPEROXIDE DISMUTASE (Mn)	7.36	21182
SOD2	SUPEROXIDE DISMUTASE (Mn)	7.78	21182
NUP3	NADH-UBIQUINONE OXIDOREDUCTASE 19 KD SUBUNIT	8.52	16884
CRYAB	ALPHA CRYSTALLIN B CHAIN	8.52	16884
HBA1	HEMOGLOBIN ALPHA CHAIN	9.44	11331
GSTP1	GLUTATHIONE S-TRANSFERASE P	5.46	22765
TPP1	TRIOSEPHOSPHATE ISOMERASE	6.38	25826
CD44	EXTRACELLULAR MATRIX RECEPTOR-III	5.06	43465
ERIB	ELONGATION FACTOR 1-BETA	4.54	30228
GLUD1	GLUTAMATE DEHYDROGENASE 1 PRECURSOR	7.26	52813
GLUD1	GLUTAMATE DEHYDROGENASE 1 PRECURSOR	6.50	52813
GLUD1	GLUTAMATE DEHYDROGENASE 1 PRECURSOR	6.91	52703
CAT	CATALASE	6.50	57735

Abbreviated Name	Protein Description	Apparent PI	Apparent MW
CAT	CATALASE	6.74	57735
CAT	CATALASE	7.07	57615
TCRP	TRANSLATIONALLY CONTROLLED TUMOR PROTEIN	4.79	21302
EGFR	EPIDERMAL GROWTH FACTOR RECEPTOR	5.75	141900
PAI-1	PLASMINOGEN ACTIVATOR INHIBITOR-1	6.50	46534
PMS2	DNA MISMATCH REPAIR PROTEIN	6.39	51925
ULAG	UNKNOWN	6.2	25000

Example 2Samples

5 Samples were taken from tumorous and normal human colorectal tissue. Epithelial cells from this colorectal tissue were isolated with magnetic particles ("Dyna-Beads"), as described in Example 1.

RNA Extraction

10 Total cellular RNA was extracted by the acid guanidinium-thiocyanate-phenol-chloroform extraction method of Chomczynsky and Sacchi, Analytical Biochemistry 162, 156-159 (1987). In summary, the procedure was as follows. To the tissue, minced and homogenised on ice, were added a 4M guanidinium thiocyanate solution containing 2-mercaptoethanol, followed by sodium acetate, 15 pH 4, phenol and chloroform. After thorough mixing and centrifugation, the aqueous phase containing the RNA was removed and the RNA precipitated with isopropanol or ethanol. After centrifuging, the RNA pellet was washed with ethanol and dissolved in SDS.

20 Total cytoplasmic RNA was extracted as described by Aubel et al, "Current Protocols in Molecular Biology" (1981), Unit 4.1, "Preparation of Cytoplasmic RNA from Tissue Culture Cells". In summary, the procedure was as follows. Cells were washed with ice-cold phosphate-buffered saline and kept on ice for all subsequent manipulations. The pellets or harvested cells were resuspended in a lysis buffer containing the nonionic detergent "Nonidet" P-40. Lysis of the plasma membranes occurs almost immediately. The intact nuclei were 25 removed by a brief microcentrifuge spin, and sodium dodecyl sulfate was added to the cytoplasmic supernate to denature protein. Protein and lipid were removed by extractions with phenol/chloroform and chloroform. In some cases, it was necessary to treat the cytoplasmic 30 extract with protease prior to extraction. The cyto- 35

plasmic RNA was recovered by ethanol precipitation and quantitated by measuring its absorbance at 260 and 280 nm.

Primer Selection

5 Arbitrary oligonucleotide (DNA) primers were used. They have not yet been optimised, but will normally have from 17 to 40 nucleotides.

Assay conditions

10 The general method was as follows. All RNAs were reverse transcribed to cDNA using an arbitrary primer, after which PCR was performed with the same primer from the product of the previous reaction in 5 cycles at a low stringency annealing temperature and 35 cycles at a high stringency temperature, all this in the presence of 15 a radioactive nucleotide so that the products could be resolved in a sequencing type gel.

20 In more detail, each reverse transcription reaction (RT) was performed in a final volume of 20 μ l using 50 ng of total RNA, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM $MgCl_2$, 10 mM DTT, 0.5 mM of each dNTP, 0.5 μ M primer, 20u RNase inhibitor and 200u reverse transcriptase (Gibco BRL). Incubation with the enzyme was performed for 1 h at 37°C and reaction was stopped by heating it at 95°C for 5 min.

25 Subsequent PCRs were performed with 2 μ l of the product of the RT, 10 mM Tris-HCl, 2.5 mM $MgCl_2$, 50 mM KCl, 0.1mg/ml gelatin, 0.1 mM of each dNTP, 2 μ M primer, 1.25u Taq polymerase (Boehringer Mannheim) and 2 μ Ci [α -33P]-dATP in a final volume of 25 μ l. The reactions 30 consisted of an initial denaturation step (94°C for 1 min), 5 cycles at low stringency conditions (94°C for 1 min; 45 seconds at the annealing temperature; 72°C for 1 min 30 sec), 35 cycles at high stringency conditions (94°C for 1 min; 60°C for 45 sec; 72°C for 1 min) and a 35 final extension (72°C for 5 min). All reactions were

- 23 -

performed in a Programmable Thermal Controller-100 (MJ Research Inc.).

PCR products were diluted (1/4) with 95% deionized formamide denaturing loading buffer (DLB), heated at 5 95°C for 3 min and immediately cooled on ice. Two μ l of each diluted sample were loaded in a 6% polyacrylamide / 8M urea denaturing sequencing gel (40 cm long, 30 cm wide, 0.4mm thick) and run at 55 W for 3 to 4 hours. The gels were dried under vacuum at 80°C and exposed to 10 a X-ray film at room temperature, without an intensifier screen, for 1-3 days. The "fingerprints" represented by the gels from the normal and abnormal tissue samples were then compared.

DNA was excised from the gel bands and sequenced. 15 It can then be determined whether it predicts proteins appearing on the 2D-gel.

20

25

30

35

CLAIMS:-

1. A method of diagnosis of an epithelial cell abnormality in a sample of tissue taken from the location of a suspected said abnormality, which comprises size-
5 separating stroma from epithelial cells, separating the epithelial cells from most of the other tissue still present, by reacting the tissue with a monoclonal antibody specific for epithelial cells, collecting the reacted cells bound to the antibody and releasing them
10 from the antibody, whereby the sample contains at least 90 percent epithelial cells by volume of the total tissue of the sample and comparing at least one phenotypic or genotypic characteristic of the sample with corresponding normal epithelial cells.
- 15 2. A method according to Claim 1, wherein the size-separation is effected by filtering the tissue sample through a filter of about 300 micrometres and collecting the epithelial cells passing through the filter.
3. A method according to Claim 2, wherein the size-
20 separation further comprises further filtering the epithelial cells through a filter of 150-250 micrometres and collecting the epithelial cells passing through the filter.
4. A method according to Claim 1, 2 or 3, wherein a phenotypic characteristic is compared by determining whether at least one protein is present in a greater or smaller concentration in the sample than in the normal cells.
5. A method according to Claim 4, wherein the protein
30 is selected from among those present in a greater or smaller amount in a two dimensional electrophoretic gel of proteins extracted from the sample than from the normal cells.
6. A method according to Claim 5, wherein the two
35 dimensional electrophoretic gel is obtainable by

(1) centrifuging 1000 microlitres of the protein extract at 10,000 G at room temperature for 5 minutes to form a pellet, dissolving the pellet in 300 microlitres of a solution containing 8M urea, 40% CHAPS, 40 mM Tris, 5 65 mM dithioerythritol and a trace of bromophenol blue and loading the resulting sample solution onto 3mm wide x 180mm long strips of immobilised pH gradient (IPG) polyacrylamide gel having a non-linear, sigmoidal (S-shaped) pH gradient;

10 (2) rehydrating the gel overnight with 25ml of an aqueous solution of 8M urea, 2% w/v CHAPS, 10 mM dithioerythritol and 2% v/v buffers of pH 3.5 to 10 and a trace of bromophenol blue;

15 (3) loading the sample solution onto IPG gel strips for first dimension electrophoresis and running the electrophoresis at a voltage which is increased linearly from 300 to 3500 V during 3 hours, then for 3 additional hours at 3500 V, and finally for 17 hours at 5000 V;

20 (4) treating the IPG gel strips with 100 ml of an aqueous solution containing 50 mM Tris-HCl, pH 6.8, 6M urea, 30% w/v glycerol, 2% w/v SDS, 2.5% v/v iodoacetamide and a trace of bromophenol blue for 5 minutes, to resolubilize the proteins and reduce any -S-S- bonds;

25 (5) preparing a polyacrylamide gradient slab gel 160 x 200 x 1.5mm from an aqueous solution containing 9 to 16% acrylamide monomer, 2.6% diacryloylpiperazine cross-linking agent, 5mM sodium thiosulfate, 0.05% tetramethyleneethylenediamine, 0.1% ammonium persulfate and 0.375M Tris-HCl buffer, pH 8.8, all percentages being w/v,

30 overlaying with sec-butanol for two hours, replacing the sec-butanol with water and standing for 15 hours, overlaying the slab gel with an aqueous solution containing 0.5% agarose, Tris-glycine-SDS at pH 8.3, at 25 mM Tris, 198 mM glycine and 0.1% SDS, heated to 70°C and

35 loading the IPG gel strips thereon for second dimension

- 26 -

electrophoresis;

(6) running the second dimension electrophoresis at a constant 40 mA/gel and at 10°C for 5 hours; and

5 (7) silver staining the gels and scanning them with a laser densitometer, to give a computer-generated image of the stained gel.

7. A method according to Claim 1, 2 or 3, wherein a genotypic characteristic is compared by determining whether the total RNA or cytoplasmic RNA is present in a 10 greater or smaller concentration in the sample than in the normal cells.

15

20

25

30

35

Colorectal Epithelia Cell 2-D PAGE Reference Map




Fig 1

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/GB 98/00881

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/574 C07K16/18

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	REYMOND ET AL: "Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis" ELECTROPHORESIS, vol. 18, no. 5, December 1997, pages 2842-2848, XP002071492 see the whole document ---	1-7
X	REYMOND M A ET AL: "Specific sample preparation in colorectal cancer." ELECTROPHORESIS, vol. 18, no. 3-4, - 1997 pages 622-624, XP002072104 see the whole document --- -/-	1-7

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

20 July 1998

05/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Routledge, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00881

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
P, Y	<p>WO 97 37226 A (MAYO FOUNDATION ; ROCHE PATRICK C (US); KLEE GEORGE G (US); LIMBURG) 9 October 1997</p> <p>séé claims 1-3,5,7-9,11,12</p> <p>see page 2, line 35 - page 3, line 21</p> <p>see page 4, line 27 - line 32</p> <p>see page 11, line 9 - line 15</p> <p>see examples 2-5</p> <p>---</p>	1-7
Y	<p>US 5 547 928 A (WU YING-JYE ET AL) 20 August 1996</p> <p>see column 7, line 43 - line 60</p> <p>see column 11, line 35 - line 38</p> <p>see column 11, line 62 - column 14, line 56</p> <p>---</p>	1-7
Y	<p>WO 97 09600 A (MEDICAL RES COUNCIL ; NEILL IAN KENNETH O (GB); LOKTIONOV ALEXANDRE) 13 March 1997</p> <p>see claims 1,10-14,17,18</p> <p>see page 10, line 4 - page 12, line 27</p> <p>see page 13, line 9 - line 19</p> <p>-----</p>	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00881

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9737226	A 09-10-1997	AU 2597397	A	22-10-1997
US 5547928	A 20-08-1996	AU 1437895	A	03-07-1995
		WO 9516919	A	22-06-1995
WO 9709600	A 13-03-1997	AU 6883096	A	27-03-1997